BRD2 and non-small cell lung carcinoma: Our data suggest that this combined treatment represents a potential therapeutic approach in more aggressive NSCLC cell types and highlights the importance of BRD2‐FTH1 interaction in lung tumorigenesis and development by inducing ferroptosis.